<?xml version="1.0" encoding="UTF-8"?>
<p id="para0010">Adolescents and young adults (AYA) ages 10–24 continue to be disproportionately burdened by the HIV epidemic. Globally, nearly one-third of new infections occur in young adults aged 15–24 years 
 <xref rid="bib0001" ref-type="bibr">[1]</xref>. AYA in sub-Saharan African (SSA) experience particularly high HIV prevalence, accounting for 85% of all adolescents living with HIV 
 <xref rid="bib0002" ref-type="bibr">[2]</xref>. Despite the high efficacy of oral antiretroviral therapy (ART) in preventing HIV-related morbidity and mortality, viral suppression among AYA living with HIV in SSA remains low 
 <xref rid="bib0003" ref-type="bibr">[3]</xref>, 
 <xref rid="bib0004" ref-type="bibr">[4]</xref>, 
 <xref rid="bib0005" ref-type="bibr">[5]</xref>, 
 <xref rid="bib0006" ref-type="bibr">[6]</xref>. Sub-optimal adherence to ART is associated with poor clinical outcomes, including increased mortality 
 <xref rid="bib0007" ref-type="bibr">[7]</xref>, drug resistance 
 <xref rid="bib0008" ref-type="bibr">[8]</xref>, and onward transmission [
 <xref rid="bib0009" ref-type="bibr">9</xref>,
 <xref rid="bib0010" ref-type="bibr">10</xref>].
</p>
